Structure Therapeutics Inc.
GPCR
$19.61
$0.241.24%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 39.72% | 18.60% | 23.94% | 53.40% | 71.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 111.46% | 75.89% | 51.84% | 75.31% | 28.20% |
| Operating Income | -111.46% | -75.89% | -51.84% | -75.31% | -28.20% |
| Income Before Tax | -136.80% | -79.70% | -46.46% | -44.46% | -12.17% |
| Income Tax Expenses | 162.26% | 237.93% | 143.59% | -77.28% | -55.08% |
| Earnings from Continuing Operations | -136.85% | -79.88% | -48.88% | -42.39% | -11.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -136.85% | -79.88% | -48.88% | -42.39% | -11.83% |
| EBIT | -111.46% | -75.89% | -51.84% | -75.31% | -28.20% |
| EBITDA | -112.07% | -76.26% | -51.42% | -74.81% | -27.67% |
| EPS Basic | -103.36% | -46.06% | -20.34% | 4.64% | 13.42% |
| Normalized Basic EPS | -103.32% | -45.93% | 8.72% | 3.24% | 13.16% |
| EPS Diluted | -103.36% | -46.06% | -20.34% | 4.64% | 13.42% |
| Normalized Diluted EPS | -103.32% | -45.93% | 8.72% | 3.24% | 13.16% |
| Average Basic Shares Outstanding | 16.47% | 23.15% | 23.72% | 49.31% | 29.17% |
| Average Diluted Shares Outstanding | 16.47% | 23.15% | 23.72% | 49.31% | 29.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |